scispace - formally typeset
L

Lisa A. Coscia

Researcher at Lehigh Valley Hospital

Publications -  60
Citations -  1722

Lisa A. Coscia is an academic researcher from Lehigh Valley Hospital. The author has contributed to research in topics: Transplantation & Pregnancy. The author has an hindex of 13, co-authored 51 publications receiving 1502 citations. Previous affiliations of Lisa A. Coscia include Thomas Jefferson University & Temple University.

Papers
More filters
Journal Article

Report from the National Transplantation Pregnancy Registry (NTPR): outcomes of pregnancy after transplantation.

TL;DR: Key benefits of the NTPR are the personal contact between registry staff and participants, the wide range of pregnancy-related variables that are analyzed, and the opportunity for health-care providers to obtain information that helps them care for transplant recipients on a case-by-case basis.
Journal ArticleDOI

Pregnancy outcomes in solid organ transplant recipients with exposure to mycophenolate mofetil or sirolimus.

TL;DR: A higher incidence of structural malformations was seen with MMF exposures during pregnancy compared to the overall kidney transplant recipient offspring, while no structural defects have as yet been reported with early pregnancy sirolimus exposures.
Journal ArticleDOI

Ciclosporin use during pregnancy.

TL;DR: The literature suggests that ciclosporin therapy during pregnancy should be carefully considered by the treating physician, but may be a safe alternative for patients with autoimmune disease refractory to conventional treatment.
Journal Article

Pregnancy after solid organ transplantation: a guide for obstetric management

TL;DR: Pregnancy should be avoided for at least 1 year after transplantation to limit the potential risks of early pregnancy that may adversely affect both allograft function and fetal well-being.
Journal ArticleDOI

Breast-feeding after transplantation.

TL;DR: Except for those medications where clinical information is inadequate (mycophenolic acid products, sirolimus, everolimus, and belatacept), the recommendation for transplant recipients regarding breast-feeding has evolved into one that is cautiously optimistic.